Zentalis Pharmaceuticals Inc

-

Stock Issuer and Owners

Home | Sign Up | Log In
Due Diligence for Asset Managers
You have viewed 8 of the 10 daily limit
Subscribe for $29/month to gain full access
New Features
Latest Fund Raises
Related People
Fund Service Providers
Startup & Company Raises
List of Funds
Boston Firms
Boston Hedge Funds
Cornell Alumni Firms
CalPERS Portfolio
NYSCRF Portfolio
User Guide
Regulatory AUM vs AUM
LP Portfolios
Related Firms
Build a Portfolio
Comprehensive Search
Keyboard
Zentalis Pharmaceuticals Inc
TickerZNTL
CIK #0001725160
CUSIP98943L107
SectorLife Sciences - Pharmaceutical Preparations
Address530 Seventh Avenue, Suite 2201, New York, NY 10018
Source [EDGAR]
Reg D Offering (Form D) Filed Raised Terms
ZENO Pharma LLC 2019-09-05 Exemption: 506(b) · Remaining: Indefinite · Duration: One year or less · Commission: $3,625,555 · Revenue: Decline to Disclose
CIK Filing 2011 - 2026
[0001725160] 10-K
[0001725160] 10-Q
[0001725160] 3
[0001725160] 4
[0001725160] 8-K
[0001725160] D
[0001725160] SC 13D
[0001725160] SC 13G
Form 13D/13G Filer Form 13D/13G Subject Filed % Owned
Squadron Capital Management LLC Zentalis Pharmaceuticals Inc [2026-03-03] 0.0
5AM Opportunities II GP LLC Zentalis Pharmaceuticals Inc [2025-12-30] 0.0
Barclays PLC Zentalis Pharmaceuticals Inc [2025-11-12] 0.0
Millennium Management LLC Zentalis Pharmaceuticals Inc [2025-02-04] 0.0
Walters William T Zentalis Pharmaceuticals Inc [2024-12-10] 0.0
Citadel Advisors LLC Zentalis Pharmaceuticals Inc [2023-11-17] 5.1
Eventide Asset Management LLC Zentalis Pharmaceuticals Inc [2023-10-10] 11.07
Tybourne Capital Management HK Ltd Zentalis Pharmaceuticals Inc [2023-02-14] 3.9
Capital International Investors Zentalis Pharmaceuticals Inc [2023-02-13] 5.3
State Street Corp Zentalis Pharmaceuticals Inc [2023-02-07] 5.4
Wellington Management Group LLP Zentalis Pharmaceuticals Inc [2023-02-06] 6.34
Matrix Capital Management Company LP Zentalis Pharmaceuticals Inc [2022-06-03] 16.45
Tybourne Capital Management HK Ltd Zentalis Pharmaceuticals Inc [2022-02-14] 5.8
Price T Rowe Associates Inc /MD/ Zentalis Pharmaceuticals Inc [2022-02-14] 9.6
Avidity Partners Management LP Zentalis Pharmaceuticals Inc [2022-02-01] 6.7
Matrix Capital Management Company LP Zentalis Pharmaceuticals Inc [2021-02-16] 0.41
Redmile Group LLC Zentalis Pharmaceuticals Inc [2021-02-16] 6.0
Vanguard Group Inc Zentalis Pharmaceuticals Inc [2021-02-10] 5.78
Sun Anthony Y Zentalis Pharmaceuticals Inc [2021-02-03] 7.3
BlackRock Inc Zentalis Pharmaceuticals Inc [2021-02-02] 5.6
FMR LLC Zentalis Pharmaceuticals Inc [2020-11-10] 0.0
Tybourne Capital Management HK Ltd Zentalis Pharmaceuticals Inc [2020-05-29] 7.4
Viking Global Investors LP Zentalis Pharmaceuticals Inc [2020-04-15] 13.0
Citadel Advisors LLC Zentalis Pharmaceuticals Inc [2020-04-09] 5.9
Form 3/4/5 Filer 2011 - 2026
Myers Scott Dunseth
Zentalis Pharmaceuticals Inc
Kariuki Enoch
Johnson David Michael
Skvarka Jan
Walker Luke Nathaniel
Campbell Shannon
Vultaggio Vincent
Eastland Julia Marie
Bruns Ingmar
Bucher James B
Walters Group
Walters Susan Berkley
Walters William Thurman
Matrix Capital Management Company LP
GOEL David E
Paul Andrea
Lackner Mark
Gallagher Cam
Hausman Diana
Epperly Melissa B
Blackwell Kimberly
Bunker Kevin D
Brownstein Carrie
Roth Iris
Sun Anthony Y
Voliotis Dimitris
Pinto Alexis
Viking Global Opportunities GP LLC
Viking Global Investors LP
Viking Global Opportunities Illiquid Investments Sub-Master
Viking Global Opportunities Portfolio GP LLC
Halvorsen Ole Andreas
Shabet Rose Sharon
Ott David C
Recurium Equity LLC
Takhar Karan S
Insider Transaction (Form 3/4/5) Date Action Shares Price Value ($)
Vultaggio Vincent
Common Stock
2026-02-10 Sell 6,894 $2.42 16,683
Bruns Ingmar
Common Stock
2026-02-09 Sell 335 $2.39 801
Eastland Julia Marie
Common Stock
2026-02-09 Sell 889 $2.39 2,125
Vultaggio Vincent
Common Stock
2026-02-09 Sell 3,379 $2.39 8,076
Eastland Julia Marie
Common Stock
2026-02-06 Sell 7,866 $2.43 19,114
Bruns Ingmar
Common Stock
2026-02-06 Sell 2,962 $2.43 7,198
Vultaggio Vincent
Common Stock
2026-02-06 Sell 29,951 $2.43 72,781
Vultaggio Vincent
Common Stock
2026-02-03 Sell 556 $2.52 1,401
Vultaggio Vincent
Common Stock
2026-02-02 Sell 2,540 $2.55 6,477
Bruns Ingmar
Stock Option (Right to Buy) · derivative
2026-01-08 Grant 365,000 $0.00
Bucher James B
Stock Option (Right to Buy) · derivative
2026-01-08 Grant 100,000 $0.00
Vultaggio Vincent
Stock Option (Right to Buy) · derivative
2026-01-08 Grant 100,000 $0.00
Eastland Julia Marie
Stock Option (Right to Buy) · derivative
2026-01-08 Grant 775,000 $0.00
Walters Group +2
Common Stock
2025-12-31 Buy 6,459,973 $1.20 7,751,968
Matrix Capital Management Company LP +1
Common Stock, par value $0.001 per share
2025-12-15 Sell 7,500,000 $1.33 9,975,000
Bucher James B
Stock Option (Right to Buy) · derivative
2025-10-01 Grant 400,000 $0.00
Skvarka Jan
Common Stock
2025-06-17 Grant 57,603 $0.00
Kariuki Enoch
Common Stock
2025-06-17 Grant 57,603 $0.00
Myers Scott Dunseth
Common Stock
2025-06-17 Grant 57,603 $0.00
Walker Luke Nathaniel
Common Stock
2025-06-17 Grant 57,603 $0.00
showing 20 of 200 most recent transactions
13F Ownership Over TimeHoldersShares Held
2026-03-31 102 41,184,981
2025-12-31 86 37,823,285
2025-09-30 99 51,164,556
2025-06-30 117 52,769,753
2025-03-31 133 55,807,434
2024-12-31 142 63,293,544
2024-09-30 136 71,528,950
2024-06-30 145 75,920,394
2024-03-31 142 80,655,420
2023-12-31 121 77,614,370
2023-09-30 137 75,797,997
2023-06-30 135 77,953,416
Form 13F Holdings
Firm Period DFND Voting Shares
Wealth Enhancement Advisory Services LLC [2026-06-30] SOLE 0 68,816
Marquette Asset Management LLC [2026-06-30] SOLE 0 28,973
Fortitude Family Office LLC [2026-06-30] SOLE 209 209
Prev | Page 1 | Next
Terms | Privacy | Providers | Companies | Guide
tony@aum13f.com